LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia) easlfibronostg on June 29, 2026 Category: Publications Tag: Identification, LiverSTAT, MAFLD, MASLD Post navigation Previous: Previous post: Fasting vs non-fasting: assessment of the impact on LIVERSTATNext: Next post: Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
